洞察当前的型菌病治疗途径
Brent Edwards1, Rebecca Ripperton1, Adeleine Tilley1
1Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, Aurora, Colorado, USA.
Antimicrobial agents and chemotherapy
|November 18, 2025
概括
菌菌症的治疗通常以可纳开始,但有些患者需要切换到其他抗真菌药物,特别是在严重的情况下. 进一步优化治疗策略是必要的,以获得更好的结果在型菌病管理.
科学领域:
- 菌类学 菌类学是指菌类学.
- 传染性疾病 传染性疾病
- 临床药理学 临床药理学
背景情况:
- 型菌,一种特定地区特有的真菌感染,通常用口服可纳治疗.
- 严重表现的菌菌症可以导致治疗失败的第一线疗法.
研究的目的:
- 分析抗菌治疗途径,以发现型菌.
- 为了确定影响治疗切换的因素.
- 根据不同的治疗疗程来比较患者的结果.
主要方法:
- 使用TrinetX数据库 (2010年1月 - 2024年3月) 的回顾性队列研究.
- 使用ICD-10-CM代码识别了患有菌菌病的患者.
- 定义治疗切换为连续≥3天抗真菌剂的变化.
主要成果:
- 在1909名患者中,有87.4%的患者开始服用可纳;11.2%的患者转换了抗真菌药物.
- 常见的切换包括流可纳到波萨可纳和安福特瑞辛B到流可纳.
- 从可纳转换为菌性脑膜炎患者的ICU入院和住院率较高.
结论:
- 可纳仍然是主要的第一线抗真菌药物用于菌菌,而安福特里辛B是常见的第二选择.
- 虽然大多数患者对初始的可纳有反应,但治疗策略的优化对于严重的菌菌菌症至关重要.
- 对于耐火病例,需要对先进的治疗方案进行进一步的研究.
相关概念视频
01:28Fungal Phylum Microsporidia
395
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
395
01:28Drug Therapy
235
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
235
01:16Therapeutic Drug Monitoring: Overview and Classification
279
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
279
01:22Drug Delivery: Miscellaneous Routes
697
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
697
01:26Drug Administration and Therapy Phases: Overview
1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
417
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
417